摘要
目的探讨人参皂甙Rg1对脑缺血-再灌注大鼠脑组织基质金属蛋白酶2（MMP-2）和基质金属蛋白酶9（MMP-9）表达的影响。方法取健康雄性SD大鼠60只。将其随机分为假手术组,模型组,尼莫地平组,人参皂甙Rg110、20、40mg/kg组,每组10只。采用线栓法栓塞2h制作大脑中动脉模型。4个药物组于术前5d至取材当日,每日清晨于腹腔注射人参皂甙Rg1（10、20、40mg/kg）及尼莫地平1mg/kg（均溶于1.5ml的等渗盐水中）,其余各组于同一时间点注射1.5ml等渗盐水,1次/d。观察再灌注24h后神经功能缺损评分;应用免疫组化、免疫印迹法检测海马CA1区MMP-2、MMP-9的表达情况。结果①假手术组、模型组,尼莫地平组和人参皂甙Rg110、20、40mg/kg组神经功能缺损评分,分别为0、2.8±0.9、1.5±0.7、2.1±0.9、1.5±0.7及1.3±1.1,差异均有统计学意义（P〈0.05）。人参皂甙Rg120、40mg/kg组与模型组比较,差异有统计学意义（P〈0.05）。人参皂甙Rg110、20、40mg/kg组与尼莫地平组比较,差异均无统计学意义（P〉0.05）。②免疫组化和免疫印迹结果显示各组均有MMP-2、MMP-9的表达,其中假手术组仅有少量表达,模型组表达量最多。与模型组比较,人参皂甙Rg110、20、40mg/kg组及尼莫地平组MMP-2、MMP-9的表达量减少,差异有统计学意义（P〈0.05）;与尼莫地平组比较,人参皂甙Rg110mg/kg组的MMP-2、MMP-9表达量显著增高,40mg/kg组显著降低（P〈0.05）,而20mg/kg组则差异无统计学意义（P〉0.05）。结论人参皂甙Rg1防治大鼠脑缺血-再灌注损伤的机制可能与抑制脑组织MMP-2、MMP-9表达有关,且以高剂量组效果较好。
Objective To investigate the effects of ginsenoslde Rgl on the expressions of matrix metalloproteinase-2 and matrix metalloproteinases-9 （ MMP-2 and MMP-9） after focal cerebral ischemia-reper- fusion in rats. Methods A total of 60 healthy male SD rats were randomly allocated to sham-operation, model, nimodipine, and ginsenoside Rgl 10, 20, and 40 mg/kg groups （n = 10 in each group）. A model of middle cerebral artelv occlusion （MCAO） for 2 hours was induced by suture method. Ginsenoside Rgl （10, 20, and 40 mg/kg） and nimodipine （dissolved in 1.5 mL isotonic saline） were injected intraperito- neally every morning from 5 days before the procedure to the day of the procedure in the 4 medication groups, and 1.5 mL isotonic saline was injected at the same time point once a day in the other groups. Neurological deficit scores were evaluated at 24 hours after reperfusion; the expressions of MMP-2 and MMP-9 in hippocampal area were analyzed by inmmnohistochemistry and Western blot. Results （1）Neurological deficit scores in the sham-operation, model, nimodipine, ginsenoside Rgl 10, 20, and 40 mg/kg groups were 0, 2.80 ±0.92, 1.50 ±0.71, 2.10±0.88, 1.50 ±0.71, and 1.30 ± 1.06, respectively.There were significant differences （ P 〈 0. 05 ）. There were significant differences between the ginsenoside Rgl 10, 20 and 40 mg/kg groups and the model group （P 〈0.05）. There were no significant differences between ginsenoside Rgl 10, 20 and 40 mg/kg groups and the nimodipine group （P 〉 0.05 ）. （2）The resuits of immunohistochemistry showed that there were expression of MMP-2 and MMP-9 in all groups, but only a few expressions in the sham-operation group, the maximum expressions was occurred in the model group. The results of Western blot showed that the expressions of MMP-2 and MMP-9 were reduced in the ginsenoside Rgl 10, 20 and 40 mg/kg groups and the nimodipine group as compared with the model group, and there were significant differences （ P 〈 0. 05 ）. The expressions of MMP2 and MMP-9 in the ginsenoside Rgl 10 mg,/kg group were increased significantly as compared with the nimodipine group, and the 40 mg/kg group were decreased significantly （ P 〈 0.05 ）, while there was no significant difference in the 20 mg/kg group （P 〉 0.05 ）. Conclusion The mechanism of ginsenoside Rgl in the prevention and treatment of cerebral ischemia-reperfusion injury in rats may be associated with the inhibition of the expressions of MMP-2 and MMP-9, and the high-dose is more effective.
出处
《中国脑血管病杂志》
CAS
2009年第2期88-92,共5页
Chinese Journal of Cerebrovascular Diseases
